Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4646373
Max Phase: Preclinical
Molecular Formula: C59H68N10O7S
Molecular Weight: 1061.32
Molecule Type: Unknown
Associated Items:
ID: ALA4646373
Max Phase: Preclinical
Molecular Formula: C59H68N10O7S
Molecular Weight: 1061.32
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C(C)C)N2Cc3ccccc3C2=O)c(OCCCCOCCCCN2CCC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)c1
Standard InChI: InChI=1S/C59H68N10O7S/c1-38(2)53(68-34-43-13-7-8-16-48(43)58(68)72)59(73)67-35-45(70)32-49(67)57(71)61-33-42-18-17-41(54-39(3)64-37-77-54)31-50(42)75-30-12-11-29-74-28-10-9-25-66-26-23-44(24-27-66)69-56-51(55(60)62-36-63-56)52(65-69)40-19-21-47(22-20-40)76-46-14-5-4-6-15-46/h4-8,13-22,31,36-38,44-45,49,53,70H,9-12,23-30,32-35H2,1-3H3,(H,61,71)(H2,60,62,63)/t45-,49+,53+/m1/s1
Standard InChI Key: VFRJYHIRKCDWOQ-ABZCTAHRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1061.32 | Molecular Weight (Monoisotopic): 1060.4993 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Jaime-Figueroa S, Buhimschi AD, Toure M, Hines J, Crews CM.. (2020) Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties., 30 (3): [PMID:31879210] [10.1016/j.bmcl.2019.126877] |
Source(1):